

101062-1P US  
Serial No. 10/556,229

October 31, 2007 Response  
to July 16, 2007- Restriction Requirement

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

<b>In re application of:</b>	Yevgeni Besidski, et al.	<b>Art Unit:</b>	1626
		<b>Examiner:</b>	Golam M. Shameem
<b>Serial No.:</b>	10/556,229	<b>Confirmation No.:</b>	3667
<b>Filed:</b>	November 9, 2005	<b>Docket No.:</b>	101062-1P US
<b>For:</b>	NEW BENZIMIDAZOLE DERIVATIVES		

---

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO RESTRICTION REQUIREMENT**

Sir:

This communication is being filed in response to the Restriction Requirement dated July 16, 2007.

Applicants hereby elect for further examination of the subject matter of Group II, claim 8. Furthermore, Applicants hereby elect *N*-(4-*tert*-Butylbenzyl)-2-(7-fluoro-1*H*-benzimidazol-1-yl)acetamide as the species.

Applicants reserve the right to pursue non-elected subject matter in future continuing and/or divisional applications.

Applicants hereby petition for a three-month extension of time to respond to the Official Action dated July 16, 2007. The fee for this extension is to be charged to Deposit Account No. 26-0166. The commissioner is hereby authorized to charge any other fees required for submission of this response to Deposit Account No. 26-0166.


101062-1P US  
Serial No. 10/556,229

October 31, 2007 Response  
to July 16, 2007- Restriction Requirement

The Commissioner is hereby authorized to charge any fee or underpayment thereof or credit any overpayment to Deposit Account No. 260166.

Early reconsideration and allowance of all pending claims is respectfully requested. The examiner is requested to contact the undersigned attorney if an interview, telephonic or personal, would facilitate allowance of the claims.

Respectfully submitted,

A handwritten signature in cursive script, reading "Karen H. Kondrad", is written over a horizontal line.

Date: October 31, 2007

By: Karen H. Kondrad  
Reg. No. 38,212